multiple immunotherapeutic options: clinical decision ......peter h. o’donnell 20 minutes case...

Copyright © 2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. 209786-2

Chair: Brian Rini

AGENDA5 minutes Introduction and Objectives

Brian Rini

20 minutes Overview of Checkpoint Inhibitors in Advanced RCCThomas Powles

20 minutes Case Study Patient With aRCC Suited for Potentially Either IO/IO or IO/TKI OptionBrian Rini

20 minutes Checkpoint Inhibitor Monotherapy in Metastatic UCPeter H. O’Donnell

20 minutes Case Study Patient With mUC Facing Treatment Decisions(1L, cis-eligible, progresses to platinum-refractory)Ajjai Alva

5 minutes Closing RemarksBrian Rini

CHAIR Brian RiniVanderbilt-Ingram Cancer Center Nashville, Tennessee, USA

FACULTYAjjai AlvaUniversity of Michigan Health Center Ann Arbor, Michigan, USA

Peter H. O’Donnell University of Chicago Chicago, Illinois, USA

Thomas Powles Barts Cancer Institute London, United Kingdom

ESMO Virtual Congress 2020 Industry Satellite Symposium

Multiple Immunotherapeutic Options: Clinical Decision Making in Advanced Renal Cell Carcinoma and Urothelial Carcinoma

Satellite Symposium Sponsored by MSD

This symposium is fully funded and organised by MSD and MSD product will be mentioned. Refer to your local Prescribing Information before prescribing, as it may differ between countries. Adverse events should be reported as per your local guidance.

Virtual Symposium Available on Demand 14 – 29 September 2020Live Q&A on Saturday, 26 September (16:45 – 17:15 CET)